Market Place
Sourcing Support
Astellas Announces Desert Oasis Healthcare Implements DIGITIVA™
20 Nov 2024 //
PR NEWSWIRE
FDA Rejects Astellas’ Effort to Extend Eye Drug Izervay Use
19 Nov 2024 //
ENPTS
FDA says no to Astellas` geographic atrophy drug
19 Nov 2024 //
PHARMAPHORUM
FDA Issues Form 483 to Astellas Pharma
15 Nov 2024 //
FDA
LabCentral and Astellas Announce Diamond Ticket Winner Quantum Sky
29 Oct 2024 //
PR NEWSWIRE
Astellas pulls application for Izervay after talks with CHMP
29 Oct 2024 //
FIERCE PHARMA
FDA approves Astellas` gastric cancer therapy
19 Oct 2024 //
REUTERS
Astellas`s Biologic Vyloy (Zolbetuximab) Receives Approval in US
18 Oct 2024 //
FDA
Astellas To Present VEOZA Data At IMS World Menopause Congress
10 Oct 2024 //
PR NEWSWIRE
FDA Grants IDE For Iota Biosciences Implantable Bladder Device
10 Oct 2024 //
PR NEWSWIRE
Astellas telegraphs new cell therapy site in Japan, 24 US layoffs
09 Oct 2024 //
FIERCE BIOTECH
Astellas pays $50M for option on AviadoBio dementia gene therapy
08 Oct 2024 //
FIERCE BIOTECH
J&J`s Erleada shows survival edge over Xtandi in real-world study
02 Oct 2024 //
FIERCE PHARMA
Singlera And Astellas Present Toxicity Detection At JSOT Meeting
01 Oct 2024 //
BUSINESSWIRE
Astellas cruises into first DTC campaign for GA med Izervay
30 Sep 2024 //
FIERCE PHARMA
Japan Approves PADCEV With KEYTRUDA For Urothelial Cancer
24 Sep 2024 //
PR NEWSWIRE
EU Approves Astellas` VYLOY For Gastric Cancers
20 Sep 2024 //
PR NEWSWIRE
Astellas Pharma`s Vyloy (zolbetuximab) Receives Approval in Europe
19 Sep 2024 //
EMA
Astellas Unveils New Life Sciences Centre In US
05 Sep 2024 //
BIOSPECTRUM ASIA
Astellas Opens Massachusetts Lab For Biotech And Academia Sharing
05 Sep 2024 //
FIERCE BIOTECH
Astellas Launches New Life Sciences Center in Cambridge, MA
05 Sep 2024 //
PR NEWSWIRE
Astellas Gene Therapies to Shut Down South San Francisco Production Plant
04 Sep 2024 //
FIERCE PHARMA
Astellas to Present VEOZAH™ Data at 2024 Menopause Society Annual Meeting
04 Sep 2024 //
PR NEWSWIRE
EC Approves Astellas` PADCEV With KEYTRUDA For Advanced Urothelial Cancer
27 Aug 2024 //
PR NEWSWIRE
Astellas Initiates Phase 3 Study Of Fezolinetant For VMS In Breast Cancer
27 Aug 2024 //
PR NEWSWIRE
Japan`s Astellas says employee indicted by China`s prosecutors
21 Aug 2024 //
REUTERS
China NMPA Approves PADCEV For Advanced Urothelial Cancer
19 Aug 2024 //
PR NEWSWIRE
Astellas` gastric cancer therapy gets UK regulator`s nod
15 Aug 2024 //
ECONOMICTIMES
CHMP Endorses New Medicines From Astellas, J&J And Ipsen
26 Jul 2024 //
FIERCE PHARMA
Astellas Gets Positive CHMP Opinion For Zolbetuximab In Gastric Cancer
26 Jul 2024 //
PR NEWSWIRE
Astellas And Osaka University Develop Stem Cell-Derived Cartilage Therapy
23 Jul 2024 //
BIOSPECTRUM ASIA
Astellas Announces Sponsored Research Agreement with UMass Chan Medical School
20 Jun 2024 //
PR NEWSWIRE
Astellas Hosts PAO Action Week To Connect Patients With Resources
10 Jun 2024 //
PR NEWSWIRE
US FDA acknowledges Astellas` resubmission of BLA for Zolbetuximab
03 Jun 2024 //
PHARMABIZ
FDA Sets New Date For Astellas` Zolbetuximab BLA Resubmission
30 May 2024 //
PR NEWSWIRE
Astellas, YASKAWA Collaborate On Cell Therapy Robotics Integration
21 May 2024 //
PR NEWSWIRE
Astellas partners with Yaskawa to create innovative cell therapy ecosystem
21 May 2024 //
BIOSPECTRUM ASIA
Bayer posts pivotal data on rival to Astellas in menopause space
18 May 2024 //
FIERCE PHARMA
Astellas Showcases Oncology Portfolio At 2024 ASCO Annual Meeting
13 May 2024 //
PR NEWSWIRE
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
02 May 2024 //
PR NEWSWIRE
Astellas, Poseida Collaborate On Allogeneic Cell Therapies In Oncology
01 May 2024 //
PR NEWSWIRE
Astellas cuts a bispecific cancer & a mitochondria-focused asset Mitobridge deal
25 Apr 2024 //
ENDPTS
Astellas` Friedreich’s ataxia gene therapy cleared for clinical study
24 Apr 2024 //
ENDPTS
Astellas` XTANDI Approved in EU for Early Prostate Cancer
23 Apr 2024 //
PR NEWSWIRE
Takeda and Astellas Agree to Establish Joint Venture Company
22 Apr 2024 //
PR NEWSWIRE
Astellas’ generic Myrbetriq defence knocked back again
20 Apr 2024 //
PHARMAPHORUM
Astellas writes down another piece of its Audentes gene therapy acquisition
16 Apr 2024 //
ENDPTS
Invenra Inc. Partners with Astellas Pharma for Bispecific Antibody Discovery
09 Apr 2024 //
BUSINESSWIRE
CytomX Announces Nomination of Candidate in PROBODY TCB Collab with Astellas
03 Apr 2024 //
GLOBENEWSWIRE
CytomX Achieves $5M Astellas Milestone
03 Apr 2024 //
CONTRACT PHARMA
Endometriosis Global Clinical Trials Review 2024
02 Apr 2024 //
BUSINESSWIRE
Delpharm Acquires Astellas’ Meppel Solid Dosage Production Facilities
02 Apr 2024 //
CONTRACT PHARMA
EU`s pharma legislative reforms `will scare investment away,` Astellas
01 Apr 2024 //
ENDPTS
China Accepts Astellas for enfortumab vedotin with KEYTRUDA for Bladder Cancer
28 Mar 2024 //
PR NEWSWIRE
Astellas wins approval in Japan for Claudin18.2 therapy after US rejection
27 Mar 2024 //
PRESS RELEASE
Astellas` VYLOY™ Approved in Japan for Treatment of Gastric Cancer
26 Mar 2024 //
PR NEWSWIRE
Astellas Receives Permanent J-code for IZERVAY™ for Geographic Atrophy
26 Mar 2024 //
PR NEWSWIRE
Astellas Receives +ve Opinion for XTANDI for Early Prostate Cancer Treatment
22 Mar 2024 //
PR NEWSWIRE
CytomX Announces Achievement in PROBODY® TCB Collaboration with Astellas
18 Mar 2024 //
GLOBENEWSWIRE
HPE Asset Upcycling Services Selected to Support Sustainability Commitments
14 Mar 2024 //
BUSINESSWIRE
